Clinical Trials on Ketosis Prone Diabetes in Belgium

Total 361 results

Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Russian Federation, Denmark, Sweden, Macedonia, The Former Yugoslav Republic of, Norway, Croatia, France, Belgium, Slovakia
Precigen Actobio T1D, LLC
TFS Trial Form Support; Intrexon Actobiotics NV, d/b/a Precigen Actobio

Completed

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)

Diabetes Mellitus, Type 1

United States, Belgium
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, France, Denmark, Sweden, Netherlands, Belgium, Finland, Macedonia, The Former Yugoslav Republic of, Norway, Israel, Spain, Croatia, Slovenia, United Kingdom, Switzerland, Ireland
Eli Lilly and Company

Completed

A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Romania, Italy, Belgium, Poland, Greece, Germany, United Kingdom, Turkey, Czech Republic, Slovakia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

Type 2 Diabetes Mellitus

United Kingdom, Belgium, Bulgaria, Spain, Slovakia, Germany, Finland
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland
AstraZeneca
Eli Lilly and Company

Completed

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Type 2 Diabetes Mellitus

United States, Czech Republic, France, Korea, Republic of, Russian Federation, Spain, Mexico, Australia, Belgium, Denmark, Germany, Hungary, Netherlands, Puerto Rico, Greece, Taiwan
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Fractyl Health Inc.

Recruiting

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes (REVITALIZE 1)

Type 2 Diabetes

United States, Ireland, United Kingdom, Belgium, Italy, Netherlands, Switzerland, Spain, France
Sanofi

Completed

Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Hyponatremia | Syndrome of Inappropriate ADH (SIADH) Secretion

France, Germany, Belgium, Hungary
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes (SimpleMix™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Poland, Spain, India, Argentina, China
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Australia, France, Italy, Korea, Republic of, Mexico, Spain, Poland, Romania, South Africa, Argentina, Austria, Belgium, Germany, Hungary, Israel, Slovakia, Greece, India, Taiwan, Canada, Czech Republic
AstraZeneca
Eli Lilly and Company

Completed

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Estonia, Romania, Finland, Netherlands, Argentina, Belgium, Germany, Portugal, United Kingdom, Greece, France, Puerto Rico
Robert Lodder
University of Kentucky

Completed

Naturlose (D-Tagatose) Efficacy Evaluation Trial (NEET)

Type 2 Diabetes

United States, India
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Type 2 Diabetes Mellitus

United States, Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, South Africa, Argentina, Canada, Germany, Hungary, Israel, Romania, Slovakia, India, Belgium, France, Puerto Rico
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

Diabetic Foot | Bacterial Infections | Osteomyelitis

China, Colombia, Estonia, Denmark, Taiwan, France, United States, Canada, Spain, Belgium, Austria, Chile, Korea, Republic of, Mexico, Slovakia, United Kingdom, Russian Federation, Croatia, Turkey, Lithuania, Poland, Latvia, Finland, H... and more
Sanofi

Completed

Obese Patients With Type 2 Diabetes (RIO-Diabetes)

Obesity | Diabetes Mellitus, Non-Insulin-Dependent | Obesity in Diabetes

United States, France, Canada, Poland, Germany, Netherlands, Belgium, Czech Republic, Argentina, Finland, United Kingdom
Provention Bio, Inc.

Completed

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT)

Type 1 Diabetes Mellitus

United States, Belgium, Canada, Czechia, France, Germany, Hungary, Poland, United Kingdom
Novo Nordisk A/S

Recruiting

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Diabetes, Type 2

United States, India, Spain, Poland, South Africa, Bulgaria, Germany, Japan, Puerto Rico
Medtronic Diabetes

Completed

INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy

Diabetes Mellitus, Type 1

Denmark, Spain, Belgium, Serbia, Sweden, Austria, France, Hungary, Israel, Italy, Lithuania, Poland, Slovakia, Slovenia
AstraZeneca

Terminated

GALLANT 4 Tesaglitazar vs. Glibenclamide

Type 2 Diabetes

Italy, Poland, South Africa, Norway, Belgium, Hungary, Slovakia, Taiwan, Philippines, Thailand, Mexico, Hong Kong, Malaysia
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes (PROMPT)

Type 2 Diabetes Mellitus

France, Italy, Turkey, Germany, United Kingdom, Belgium, Spain
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Takeda
Eli Lilly and Company

Completed

Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes (PROactive)

Diabetes Mellitus

Estonia, Latvia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, Netherlands, Norway, Poland, Slovakia, Sweden, Switzerland, United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (PIONEER 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Austria, Belgium, Norway, Turkey, Switzerland, Argentina, Korea, Republic of, Brazil, Egypt
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Mexico, Netherlands, Russian Federation, India, Belgium, Japan, Romania, Italy
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Germany, United Kingdom, Austria, Belgium, France, Ireland
Novo Nordisk A/S

Terminated

Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes (iINHALE 7)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Mexico, Poland, Canada, Austria, Belgium, Argentina, France, Bulgaria, Turkey
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, United Kingdom, Spain, Denmark, France, Netherlands, Austria, Hungary, Russian Federation, Germany, Turkey, Italy, Bulgaria, Romania, Belgium, Switzerland, Slovenia, Czech Republic
AstraZeneca
Eli Lilly and Company

Completed

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Diabetes Mellitus, Type 2

Belgium, United States, Australia, Portugal, Germany, Puerto Rico, Spain, Netherlands, Brazil, Finland, Norway, Poland, Sweden
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)

Type 2 Diabetes

United States, Puerto Rico, Spain, Germany, Argentina, Brazil, Turkey, Hungary, Italy, Russian Federation, Slovakia, Belgium, Czechia, Greece, Mexico, Romania
Sanofi

Completed

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)

Diabetes

Peru, Ukraine, Colombia, Egypt, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates
Novo Nordisk A/S

Recruiting

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PIONEER TEENS)

Diabetes Mellitus, Type 2

United States, Malaysia, United Kingdom, Australia, Netherlands, Portugal, Austria, Israel, India, Greece, Lebanon, Mexico, New Zealand, North Macedonia, Puerto Rico, Romania, Russian Federation, Ukraine, Morocco, Belgium, Czechia, Taiw...
AstraZeneca
Bristol-Myers Squibb

Completed

18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)

Type 2 Diabetes

Mexico, South Africa, Norway, Argentina, Belgium, Denmark, Sweden, France, Italy
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem2)

Type 1 Diabetes Mellitus

Israel, Italy, Spain, Bulgaria, Hungary, Poland, Slovakia, United Kingdom, Austria, Belgium, France, Germany, Lithuania, Netherlands, Romania, Sweden, Switzerland
Novo Nordisk A/S

Completed

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Diabetes Mellitus, Type 1

United Kingdom, Denmark, Sweden, Netherlands, Belgium, Finland, France, Australia, Ireland, Norway
Sanofi

Terminated

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)

Sleep Initiation and Maintenance Disorders

United States, Canada, Brazil, Russian Federation, Australia, Germany, Italy, Spain, Turkey, India, Malaysia, Singapore, Belgium, Czech Republic, Mexico, Argentina, Austria, Colombia, Chile, South Africa, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy (DUAL™IV)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Puerto Rico, Germany, Turkey, Canada, Bulgaria
Lexicon Pharmaceuticals
Sanofi

Completed

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone (inTandem3)

Type 1 Diabetes Mellitus (T1DM) | High Level of Sugar (Glucose) in the Blood

United States, Australia, Spain, Belgium, Argentina, Bulgaria, Canada, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Slovakia, South Africa, United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 1)

Type 1 Diabetes Mellitus

United States, Austria, Germany, Italy, Spain, United Kingdom, Belgium, Mexico, Israel, Hungary, Canada, Australia, Denmark, Sweden, Romania, France, Finland
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Spain, Denmark, Austria, Belgium, Serbia, Germany, Canada, France, Finland, Norway, Czech Republic
Novo Nordisk A/S

Completed

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (Onset® 5)

Diabetes | Diabetes Mellitus, Type 1

United States, Russian Federation, United Kingdom, Canada, France, Netherlands, Belgium, Germany, Slovenia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

United States, India, Russian Federation, Belgium, Spain, Israel, Croatia, Serbia, North Macedonia, South Africa, Slovenia, Brazil, Poland, Canada, Czechia
Novo Nordisk A/S

Completed

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Italy, Poland, Russian Federation, United Kingdom, Canada, Denmark, Sweden, Austria, Belgium, Spain, Ireland, Norway, Serbia, Finland, Portugal, Ukraine
Amgen

Completed

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Type 2 Diabetes | Hypercholesterolemia | Mixed Dyslipidemia

United States, Italy, Belgium, Spain, Canada, Poland, Mexico
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2)

Type 1 Diabetes Mellitus

United States, Germany, Belgium, Canada, Japan, Chile, United Kingdom, Poland, Netherlands, Argentina, Sweden, Russian Federation, Switzerland
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O)

Type 2 Diabetes Mellitus

Estonia, Spain, Ukraine, Italy, Germany, Canada, Mexico, United States, Argentina, Bulgaria, Chile, Denmark, Finland, Hungary, India, Korea, Republic of, Latvia, Lithuania, Norway, Peru, Poland, Romania, Russian Federation, Serbia, Slov... and more

Clinical Trials on Ketosis Prone Diabetes in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations